UNITAID on Trans-Pacific Partnership Agreement

/ By / Others, Uncategorized

UNITAID, which is hosted and administered by World Health Organisation, in its report titled “The Trans-Pacific Partnership Agreement: Implications for Access to Medicines and Public Health” (“Report”), voiced its opposition against Trans-Pacific Partnership Agreement (“TPPA”) which encapsulates TRIPS plus commitments. TPPA is positioned as a model agreement for future trade agreements including those involving developing countries. According to the Report, such agreements will delay generic market entry and competition which will in turn lead to increased prices of pharmaceuticals and […]

UNITAID on Trans-Pacific Partnership Agreement Read More »

Thomson Reuters’ Report on Research and Innovation Performance: India sees increase in research output; patent applications stable for the past decade

/ By / Innovation, Patent

Thomson Reuters has recently come out with a report titled ‘Research and Innovation Performance of the G20’ where scientific research and patent information has been mined to study the scale and impact of scientific research and innovation in the G20. The data was mined from Thomson Reuters’ proprietary databases including Web of Science and Derwent World Patent Index. Scientific Research: The Report casts light on India’s growing influence in the sphere of scientific research.  India, along with China, South Korea, Saudi

Thomson Reuters’ Report on Research and Innovation Performance: India sees increase in research output; patent applications stable for the past decade Read More »

SpicyIP Tidbit: Sun Pharmaceuticals-Ranbaxy deal

/ By / Others

Sun Pharmaceuticals, one of India’s largest drugmakers is acquiring competitor Ranbaxy Laboratories for $3.2 billion from Japan’s Daiichi Sankyo Co. Daiichi Sankyo, the majority shareholder in Ranbaxy will acquire a 9% stake in Sun Pharmaceuticals after the deal and also has an option to send a board member to Sun Pharmaceuticals. This deal, which comes when Ranbaxy is under some regulatory scrutiny in the USA (according to media reports), will catapult the combined entity to India’s largest pharma company and

SpicyIP Tidbit: Sun Pharmaceuticals-Ranbaxy deal Read More »

SpicyIP Weekly Review – 31st March to 6th April

/ By / Others

We started this week with Mathews reporting on the stay granted by the IPAB on the Chennai Patent Office’s order revoking Pfizer’s patent in the drug Detrol (read our original post here). The IPAB reasons that the balance of convenience is very much in favour of the petitioner for granting the relief of stay and that Ranbaxy had adequate time to appear and argue the matter and that there was no need to delay the matter any longer. Anubha then

SpicyIP Weekly Review – 31st March to 6th April Read More »

SpicyIP Tidbit: Astrazeneca sues Glenmark for infringement of anti-diabetes drug Saxagliptin

/ By / Drug Regulation, Patent

UK based Astrazeneca has sued Indian drugmaker Glenmark for patent infringement of its drug Saxagliptin, an anti-diabetes drug. The dispute arose due to Glenmark’s production and export of the drug Saxagliptin Monohydrate (API) in India, based on the Controller’s permission allowing Glenmark to manufacture the drug. Astrazeneca holds a patent in India until 2025 for the same drug. The Delhi High Court has granted a  status quo order on the matter, allowing Glenmark to continue manufacturing the drug. Glenmark has

SpicyIP Tidbit: Astrazeneca sues Glenmark for infringement of anti-diabetes drug Saxagliptin Read More »

At SpicyIP We Love IPR, Ab Ki Baar…

/ By / Copyright, Trademark

 Unless you have been hibernating or have a strong resolve to completely avoid social media, chances are that you have come across the latest viral ‘Ab Ki Baar, Modi Sarkar’ meme doing the rounds. Apart from attempting to make a few funny slogans myself, the ubiquity of the meme forced me to think about the IPR issues involved. In an earlier post, we have discussed the copyrightability of memes, where Devika concluded that a meme is usually protected from an

At SpicyIP We Love IPR, Ab Ki Baar… Read More »

Join INTA and More than 7,700 Trademark Professionals in Hong Kong

/ By / Sponsored

As many of you know, this year the INTA Annual Meeting will be hosted for the first time in Asia. Although the Hong Kong Meeting is still one month away, more than 7,700 attendees from over 140 countries have already registered. See who is attending! Registrants from the South Asian region have already surpassed the number of registrants from the same region in 2013 by 10%. Here are some programs that are specially planned for those interested in the South Asia region: What Role

Join INTA and More than 7,700 Trademark Professionals in Hong Kong Read More »

IPAB guards against Trademark Bullying- Jones Investment Co v. Vishnupriya Hosiery Mills

/ By / Trademark

In a decision delivered on 24th February, 2014, the Intellectual Property Appellate Board (IPAB) affirmed that a multinational company cannot claim infringement of trademark by a local Indian company purely based on international presence, unless they can expressly establish that their presence extends to India or precedes that of the Indian company. The appellant in the case is Jones Investment Co, an American company which uses the trademark ‘Jones New York’ internationally in relation to apparel, hosiery, footwear, etc. The

IPAB guards against Trademark Bullying- Jones Investment Co v. Vishnupriya Hosiery Mills Read More »

Health Ministry’s plans to compulsorily licence Dasatinib hits DIPP roadblock

/ By / Drug Regulation, Patent

News reports indicate that the Government has been treading carefully regarding decisions to compulsorily licence drugs. This is in the wake of severe criticism of the Indian IP regime from Big Pharma and a few first world countries, most notably the US. As per the report, the Government was considering granting compulsory licence to three drugs, and ultimately the decision boiled down to one drug- Dasatinib. Dasatinib is the cancer drug for which BDR Pharma’s application for a compulsory licence was rejected by the Indian

Health Ministry’s plans to compulsorily licence Dasatinib hits DIPP roadblock Read More »

Spicyip Tidbit: Bureaucracy may Cost the OSDD a Year of Funding

/ By / Innovation

The Times of India reports that the funding for the Open Source Drug Discovery (OSDD) project of the Council of Scientific and Industrial Research (CSIR) came to an end at the conclusion of the financial year that ended two days ago (we had blogged about the launch of the OSDD here and its progress here). This was shockingly due to the Ministry of Science and Technology sitting on a cabinet note that would approve their funding for well over six

Spicyip Tidbit: Bureaucracy may Cost the OSDD a Year of Funding Read More »

Scroll to Top